30 newly listed drugs are quickly listed on the Internet through the "green channel"!

It is worth noting that the bevacizumab variety has welcomed three more companies, namely BeiGene (Bio-Tech is responsible for the production), Dong Yao Pharmaceutical and Betta Pharmaceuticals, and the competition is about to become fierce

Bevacizumab injection is widely used in the treatment of various malignant tumors, and it is the most competitive biosimilar drug variety.

Bevacizumab has attracted so many companies to enter the market, which is not unrelated to its broad market prospects and potential space for drug combination

With the development of domestic pharmaceutical companies, the market share of Roche's bevacizumab injection has rapidly declined, falling below 40% from the exclusive market in 2018 to the first half of 2021

According to the Frost & Sullivan report, the market size of bevacizumab in China will increase to 6.

Oseltamivir has a company to terminate the research and development

According to data from Minet.

  In the market, there are 5 manufacturers of oseltamivir capsules, namely Roche, Yichang Dongguang Changjiang Pharmaceutical Co.

  However, some companies have opted out

  In addition, Qilu Pharmaceutical's recombinant human follicle-stimulating hormone for injection, Sanofi's dupilimumab injection and Zai Lab's omacycline tosylate have also attracted market attention

  At the end of last year, Qilu Pharmaceutical's recombinant human follicle-stimulating hormone for injection was approved for marketing

  Dupilumab, as the world's first approved targeted biologic for the treatment of moderate to severe atopic dermatitis, has global sales of US$4.

  As for the promotion of omacycline tosylate, Zai Ding chose to join hands with Hisun

R&D investment is soaring, Hengrui, Qilu and CSPC are competing for the first place

  According to the data, it is expected that in 2021, the R&D investment of Hengrui, Qilu and CSPC will reach a new high, with a total of more than 10 billion yuan
.
In recent years, Hengrui Pharmaceutical's R&D investment has maintained rapid growth year after year, reaching nearly 5 billion yuan in 2020 and more than 4 billion yuan in the first three quarters of 2021.
R&D investment accounts for more than 20% of revenue; Qilu Pharmaceutical's R&D investment accounts for sales revenue The proportion continued to rise, increasing to 8% to 10%
.
In 2020, the company's R&D investment was 2.
65 billion yuan, and it is expected to reach 3.
9 billion yuan in 2021; in 2020, CSPC's investment in R&D innovation hit a new high, with a total investment of nearly 3 billion yuan in research and development
.
In the first three quarters of 2021, CSPC's R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
  

  With increasing investment in R&D, companies are also reaping innovative results one after another
.
In addition to the 10 innovative drugs already on the market, Hengrui currently has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being conducted at home and abroad
.
At present, Qilu Pharmaceutical has 23 Class 1 new drugs in the pipeline of clinical application and above, including 17 innovative macromolecular drugs, which are deployed in the fields of monoclonal antibody, double antibody and ADC
.
CSPC has about 300 products under development, of which about 100 are innovative drug products, and more than 60 new products are expected to be launched in the next three years
.
It is foreseeable that in the future, competition among enterprises will extend from common varieties to innovative drugs, bringing more treatment options to the clinic
.